Iovance Biotherapeutics (NASDAQ: IOVA) is generating interest among investors as its shares have underperformed despite promising developments. The company earned approval for its melanoma treatment, Amtagvi, in 2024, which has seen impressive sales growth, reaching $263.5 million last year—a 61% increase year-over-year. With a potential expansion into European and Australian markets, Iovance is positioned to exceed $1 billion in annual sales by 2030, bolstered by ongoing clinical trials for additional indications.

However, investing in Iovance carries significant risks typical of smaller biotech firms. The complexities of its tumor-infiltrating lymphocyte therapies, which require specialized manufacturing and administration, pose operational challenges. Any clinical or regulatory setbacks could lead to substantial volatility in its stock price.

For market professionals, a cautious approach is advisable. While Iovance’s growth potential is compelling, initiating a small position may mitigate risk while allowing for exposure to its upside.

Source: fool.com